

Electronic Acknowledgement Receipt

EFS ID:	4304844
Application Number:	10809635
International Application Number:	
Confirmation Number:	8938
Title of Invention:	DIPEPTIDYL PEPTIDASE INHIBITORS
First Named Inventor/Applicant Name:	Jun Feng
Customer Number:	32793
Filer:	David J. Weitz/Matt Russell
Filer Authorized By:	David J. Weitz
Attorney Docket Number:	DPP-IV-5004-U
Receipt Date:	17-NOV-2008
Filing Date:	24-MAR-2004
Time Stamp:	20:06:49
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$990
RAM confirmation Number	4971
Deposit Account	502256
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/Message Digest	Multi Part /.zip	Pages (if appl.)
1	Request for Continued Examination (RCE)	DPP4-5004-U_RCE_11-17-2008.pdf	737846 4ab759da67f3b542fb9d9e23ce0ab97aa76 917b3	no	3

Warnings:

Information:

2		DPP4-5004-U_Amendment_to_Note_Allowance_11-17-2008.pdf	686053 5b0f26c04ff63f3a42cd66c9a50514e806623 a96	yes	16
---	--	--	--	-----	----

Multipart Description/PDF files in .zip description

	Document Description	Start	End
	Amendment After Final	1	1
	Claims	2	15
	Applicant Arguments/Remarks Made in an Amendment	16	16

Warnings:

Information:

3	Information Disclosure Statement (IDS) Filed (SB/08)	DPP4-5004-U_IDS_11-17-2008.pdf	1434342 6155d3ee152ae9324e0065f6e06570568a0 a1b22	no	6
---	--	--------------------------------	---	----	---

Warnings:

Information:

4	NPL Documents	Abstract-of-EP900568-A2.pdf	90691 55092ef6d56d899d13f9580ad26db369d42 22884	no	3
---	---------------	-----------------------------	---	----	---

Warnings:

Information:

5	NPL Documents	Alagarsamy-Synthesis_and_Pharmacological-Med_Chem_lab-XP008084498.pdf	187413 570f9a61882b3f95c269d338d4b6dc2c69c3 9302	no	2
---	---------------	---	--	----	---

Warnings:

Information:

6	NPL Documents	Belgodere_Chem_Abstracts_1976_85-9.pdf	47519 cca3a430ae148db7c70d95ee586e995378e 50797	no	3
---	---------------	--	---	----	---

Warnings:

Information:					
7	NPL Documents	CAPLUS_Abstract_104_68665.pdf	46269 ba676840608/d9f4af082d0898257f2587c6ff88	no	2
Warnings:					
Information:					
8	NPL Documents	CAPLUS_Abstract_105_191027.pdf	43845 5b042a941138862553e3f227b272cdb6ee528062	no	2
Warnings:					
Information:					
9	NPL Documents	DB-Beilstein-DE-1989-XP00232086.pdf	32981 56f1d2d2af6202a822f7e5c34afee27eba015e95	no	2
Warnings:					
Information:					
10	NPL Documents	Desai_Synthesis_anti-HIV-Indian_J_Experimt_Bio-XP008084509.pdf	284785 232f7094312b2f5ceacd43265b016032fd877e5	no	4
Warnings:					
Information:					
11	Foreign Reference	EP00442473A1.pdf	1729807 5282262a6ea126edd930ebec964770bc5e57f23d	no	40
Warnings:					
Information:					
12	Foreign Reference	EP00748800A2.pdf	3846115 eafae0cea9c29354a5717c94c84ed2e404ab3b0f	no	51
Warnings:					
Information:					
13	Foreign Reference	EP01229024A1.pdf	765065 075adc357f16c5c1a27c091bbf360b3db9b982d1	no	88
Warnings:					
Information:					
14	Foreign Reference	EP01398032A1.pdf	2451091 d184b6bcd7c727449cc9acf1347bbd74cf26000f	no	85
Warnings:					
Information:					
15	NPL Documents	Kazuo_et_al_XP008082357.pdf	564562 40564e0eaeb2d4be75ef5f8ccb2a723683c73862	no	6
Warnings:					

Information:					
16	NPL Documents	Kotani_JMED-1997_40_684-69 4_XP000652330.pdf	1223662 e3bddac66124e02a586c1b21cab30728bdf b2943	no	12
Warnings:					
Information:					
17	NPL Documents	Mall_et_al- Reactivity_Differences_Cis- Trans-- J_of_Organic_Chem-52-4812. pdf	356444 8244c6465412313e790174ac2035f4d6e0b 05483	no	3
Warnings:					
Information:					
18	NPL Documents	Misra-Synthesis_N-aryl-n- Pharmacol-1979_XP008084507 .pdf	483736 6bed64acd5d18d67b75639b50664afedc1 a5181	no	8
Warnings:					
Information:					
19	NPL Documents	Molina_et_al-Synthesis-1992-3- DE-XP002390907.pdf	186799 6bcd252994705533024394c583908f7434ac e6b8	no	6
Warnings:					
Information:					
20	NPL Documents	Schilling_et_al- CA_143-347172-2005.pdf	34967 f9f8a2cea96819ae24d3d0044d03cc2dd8f2 e02f	no	2
Warnings:					
Information:					
21	NPL Documents	Tam_et_al-J-ORG- CHEM-1979-44-XP002390906. pdf	347840 5e55d127497c29f5c5e2d2bcd58083d4b9b 106ee	no	8
Warnings:					
Information:					
22	NPL Documents	Wang-Studies_Quinazolinones- Biorgan_Medic_Chem- XP009077496.pdf	330685 44790baf48e67ca6d8b53607105491d8e1f 113be	no	4
Warnings:					
Information:					
23	Foreign Reference	WO05095381A1.pdf	8641200 18e26098db01f429d35fb7edacd44d5c595 e3198	no	170
Warnings:					
Information:					
24	Foreign Reference	WO9515309A.pdf	1471747 d17586c2165cc8dcaec1f888c4b32788031 aedd	no	57
Warnings:					

Information:					
25	Foreign Reference	WO27033265A1.pdf	3223471 6a082b9fd7ee290c8f76f3649a5b963b654c 9a6d	no	58
Warnings:					
Information:					
26	Foreign Reference	WO2007033266_A2_A3.pdf	3652658 48243458441a5a49ccc5b223577eb407d47 2ebc9	no	67
Warnings:					
Information:					
27	Foreign Reference	WO2007033350_A1.pdf	3301942 2c72ea22890d21f95f5bca020221ed91bdb 60e6b	no	59
Warnings:					
Information:					
28	NPL Documents	Alagarsamy-Synthesis_Analgesic-Bio_Pharm-Bull_25-11-1432-1435-2002-XP008084513.pdf	291155 0987c3a330f20d4f0479926bc72bee30ba3 dcbaa	no	4
Warnings:					
Information:					
29	Fee Worksheet (PTO-06)	fee-info.pdf	32125 5b4bebda69dde78c30621bdade4ce3273a 28b596	no	2
Warnings:					
Information:					
Total Files Size (in bytes):					36526815
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p>New Applications Under 35 U.S.C. 111 If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p>National Stage of an International Application under 35 U.S.C. 371 If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p>New International Application Filed with the USPTO as a Receiving Office If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					